Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.2
Journals
JoF
Sections
Pathogenic Fungal Infections in Cancer and Transplant Patients
share announcement

Pathogenic Fungal Infections in Cancer and Transplant Patients

A topical collection in Journal of Fungi (ISSN 2309-608X). This collection belongs to the section "Fungal Pathogenesis and Disease Control".

Viewed by 3128

Editors

Prof. Dr. Issam I Raad

E-Mail Website
Collection Editor
Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: fungal infections in cancer and SCT; CLABSI prevention and management; febrile neutropenia; procalcitonin and biomarkers of sepsis in cancer
Dr. Marjorie Vieira Batista

E-Mail
Collection Editor
Department of Infectious Diseases, AC Camargo Cancer Center, São Paulo 01509-010, SP, Brazil
Interests: fungal infection; hematopoietic stem cells; stem cell transplantation

Topical Collection Information

Dear Colleagues,

This Topical Collection, entitled "Pathogenic Fungal Infections in Cancer and Transplant Patients", aims to present recent research on any aspect of invasive fungal infections in immunocompromised cancer and stem cell and solid organ transplant patients. Patients with prior CAR-T cell intervention are also of interest. This field has seen major advances over the last 5 to 10 years, which will be highlighted in this Topical Collection. Some of the focal areas include, but are not limited to, the following:

  1. The changing epidemiology and risk factors of fungal infections in cancer and transplant patients.
  2. Pathogenesis of fungal infections in cancer and transplant patients.
  3. Immunology of fungal infections in cancer and transplant patients.
  4. Biofilm and pathogenic fungal infections in cancer and transplant patients.
  5. Advances in the diagnosis, prevention, management, and treatment of fungal infections in cancer and transplant patients. 

Reviews, original research, and communications are welcome. 

Prof. Dr. Issam I Raad
Dr. Marjorie Vieira Batista
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pathogenic fungal infections
  • fungal infections in cancer
  • fungal infections in stem cell transplant
  • fungal infections in solid organ transplant

Published Papers (2 papers)

Download All Papers

2025

Jump to: 2023

9 pages, 383 KiB  
Article
Decreased Frequency and Improved Outcomes in Invasive Aspergillosis Caused by Aspergillus terreus After the Introduction of Anti-Mold Azole Agents: A 30-Year Study at a Tertiary Cancer Center
by Ray Y. Hachem, Hiba Dagher, Anne-Marie Chaftari, Ying Jiang, Andrea Haddad, Saliba Wehbe, Jishna Shrestha, Robin Sherchan, Peter Lamie, Jennifer Makhoul, Patrick Chaftari and Issam I. Raad
J. Fungi 2025, 11(2), 119; https://doi.org/10.3390/jof11020119 - 5 Feb 2025
Viewed by 526
Abstract
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with hematological malignancy (HM) and hematopoietic stem cell transplant (HSCT) recipients. Aspergillus terreus is associated with worse outcomes than non-terreus Aspergillus species. Since the introduction of anti-mold azoles in 2002, [...] Read more.
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with hematological malignancy (HM) and hematopoietic stem cell transplant (HSCT) recipients. Aspergillus terreus is associated with worse outcomes than non-terreus Aspergillus species. Since the introduction of anti-mold azoles in 2002, there have been limited data on the etiology of IA. We retrospectively compared characteristics, antifungal treatments, and outcomes between patients with HM or HSCT infected with A. terreus and those with non-terreus Aspergillus between July 1993 and July 2023. We also examined trends over time in rates of A. terreus and outcomes of this infection. A total of 699 patients with culture-documented IA were analyzed, 537 with non-terreus species and 162 with A. terreus. Types of underlying malignancy, neutropenia, graft-versus-host disease, and anti-mold prophylaxis were similar between the groups. ICU stays and mechanical ventilation were more common among patients with A. terreus (p = 0.002 and 0.003, respectively). The rate of A. terreus decreased significantly from 35.9% during 1993–2003 to 11.2% during 2004–2013 and 16.7% during 2014–2023 (p < 0.0001 each). IA caused by A. terreus showed significant improvements in response to therapy and in overall and IA-associated mortality in the last two decades compared to the first (p < 0.0001). In conclusion, the increased use of anti-mold azoles after 2003 improved outcomes for HM patients with IA caused by A. terreus. Full article
►▼ Show Figures

Figure 1

2023

Jump to: 2025

14 pages, 2270 KiB  
Article
Invasive Aspergillosis among Lung Transplant Recipients during Time Periods with Universal and Targeted Antifungal Prophylaxis—A Nationwide Cohort Study
by Cornelia Geisler Crone, Signe Marie Wulff, Bruno Ledergerber, Jannik Helweg-Larsen, Pia Bredahl, Maiken Cavling Arendrup, Michael Perch and Marie Helleberg
J. Fungi 2023, 9(11), 1079; https://doi.org/10.3390/jof9111079 - 4 Nov 2023
Cited by 1 | Viewed by 1974
Abstract
The optimal prevention strategy for invasive aspergillosis (IA) in lung transplant recipients (LTXr) is unknown. In 2016, the Danish guidelines were changed from universal to targeted IA prophylaxis. Previously, we found higher rates of adverse events in the universal prophylaxis period. In a [...] Read more.
The optimal prevention strategy for invasive aspergillosis (IA) in lung transplant recipients (LTXr) is unknown. In 2016, the Danish guidelines were changed from universal to targeted IA prophylaxis. Previously, we found higher rates of adverse events in the universal prophylaxis period. In a Danish nationwide study including LTXr, for 2010–2019, we compared IA rates in time periods with universal vs. targeted prophylaxis and during person-time with vs. person-time without antifungal prophylaxis. IA hazard rates were analyzed in multivariable Cox models with adjustment for time after LTX. Among 295 LTXr, antifungal prophylaxis was initiated in 183/193 and 6/102 during the universal and targeted period, respectively. During the universal period, 62% discontinued prophylaxis prematurely. The median time on prophylaxis was 37 days (IQR 11–84). IA was diagnosed in 27/193 (14%) vs. 15/102 (15%) LTXr in the universal vs. targeted period, with an adjusted hazard ratio (aHR) of 0.94 (95% CI 0.49–1.82). The aHR of IA during person-time with vs. person-time without antifungal prophylaxis was 0.36 (95% CI 0.12–1.02). No difference in IA was found during periods with universal vs. targeted prophylaxis. Prophylaxis was protective of IA when taken. Targeted prophylaxis may be preferred over universal due to comparable IA rates and lower rates of adverse events. Full article
►▼ Show Figures

Figure 1

Back to TopTop